VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
OMCL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
OMCLOmnicell, Inc.
$40.92$1.9B
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders
HomeStocksOMCLFinancials

Omnicell, Inc. (OMCL) Financials

26Y historyFree accessUpdated daily

Revenue growth remains highly sensitive to hospital capital expenditure cycles, evidenced by a swing from a 15.3% contraction in 2024Q1 to an 18.6% expansion by 2024Q4.

OMCL Income Statement

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00
Sales/Revenue1.23B1.18B1.11B1.15B1.3B1.13B892.21M897.03M787.31M716.16M692.62M484.56M440.9M380.58M314.03M245.53M222.41M213.46M251.87M213.08M154.71M121.52M123.94M102.13M87.69M86.9M67.36M
Revenue Growth %7.86%6.53%-3.04%-11.48%14.48%26.88%-0.54%13.94%9.93%3.4%42.94%9.9%15.85%21.2%27.89%10.4%4.19%-15.25%18.2%37.73%27.31%-1.95%21.36%16.46%0.91%29%-
Cost of Goods Sold692.19M681.4M641.24M647.18M706.96M577.37M478.92M460.12M414.98M394.08M378.82M236.63M207.04M177.19M143.47M109.75M104.49M108.24M123.23M99.77M69.19M54.51M52.03M42.46M36.42M32.77M26.58M
COGS % of Revenue-57.51%57.65%56.42%54.55%51%53.68%51.29%52.71%55.03%54.69%48.83%46.96%46.56%45.69%44.7%46.98%50.71%48.93%46.82%44.72%44.86%41.98%41.58%41.53%37.71%39.45%
Gross Profit532.87M503.44M471M499.93M588.99M554.65M413.29M436.91M372.33M322.09M313.8M247.93M233.86M203.4M170.55M135.78M117.92M105.22M128.63M113.31M85.52M67.01M71.91M59.67M51.27M54.13M40.79M
Gross Margin %43.5%42.49%42.35%43.58%45.45%49%46.32%48.71%47.29%44.97%45.31%51.17%53.04%53.44%54.31%55.3%53.02%49.29%51.07%53.18%55.28%55.14%58.02%58.42%58.47%62.29%60.55%
Gross Profit Growth %-6.89%-5.79%-15.12%6.19%34.2%-5.41%17.35%15.6%2.64%26.57%6.02%14.98%19.26%25.61%15.15%12.07%-18.2%13.53%32.49%27.62%-6.81%20.51%16.37%-5.29%32.72%-
Operating Expenses499.24M498.28M470.67M519.26M591.31M465.15M377.77M358.56M327.94M316.33M307.32M202.74M184.28M168.1M143.47M119.56M107.23M103.24M111.29M95.08M76.27M69.31M61.19M51.73M54.74M54.71M57.41M
OpEx % of Revenue-42.05%42.32%45.27%45.63%41.09%42.34%39.97%41.65%44.17%44.37%41.84%41.8%44.17%45.69%48.69%48.22%48.36%44.19%44.62%49.3%57.04%49.37%50.65%62.42%62.96%85.23%
Selling, General & Admin409.57M409.61M380.25M425.97M486.34M389.43M307.61M289.92M263.1M250.31M249.52M167.58M156.47M139M119.75M97.52M86.23M85.67M93.1M80.03M65.04M59.7M52.08M42.78M44.77M43.68M46.14M
SG&A % of Revenue-34.57%34.19%37.13%37.53%34.4%34.48%32.32%33.42%34.95%36.03%34.58%35.49%36.52%38.13%39.72%38.77%40.13%36.96%37.56%42.04%49.13%42.02%41.89%51.05%50.27%68.49%
Research & Development89.67M88.67M90.41M93.29M104.97M75.72M70.16M68.64M64.84M66.02M57.8M35.16M27.8M29.11M23.73M22.04M21.01M17.57M18.2M15.05M11.22M9.61M9.11M8.95M9.97M11.03M11.27M
R&D % of Revenue-7.48%8.13%8.13%8.1%6.69%7.86%7.65%8.24%9.22%8.34%7.26%6.31%7.65%7.56%8.98%9.45%8.23%7.22%7.06%7.25%7.91%7.35%8.76%11.37%12.69%16.73%
Other Operating Expenses0000000000000-178K-99K000000000000
Operating Income33.63M5.16M337K-19.33M-2.32M89.51M35.53M78.35M44.39M5.75M6.48M48.63M49.58M35.3M27.08M16.22M9.53M669K17.34M18.22M9.26M-2.71M10.55M6.98M-5.9M-430K-19.53M
Operating Margin %2.75%0.44%0.03%-1.69%-0.18%7.91%3.98%8.73%5.64%0.8%0.94%10.04%11.25%9.27%8.62%6.61%4.28%0.31%6.88%8.55%5.98%-2.23%8.51%6.84%-6.73%-0.49%-29%
Operating Income Growth %-1431.16%101.74%-732.07%-102.6%151.95%-54.66%76.5%671.5%-11.22%-86.67%-1.92%40.47%30.34%66.95%70.29%1323.92%-96.14%-4.85%96.89%442.18%-125.65%51.02%218.31%-1272.79%97.8%-
EBITDA111M83.95M90.09M76.23M96.85M174.44M107.12M142.47M95.74M57.27M64.84M74.27M69.86M53.66M40.41M24.2M18.14M10.1M26.29M22.83M12.97M1.49M14.63M10.49M-2.88M3.29M-15.88M
EBITDA Margin %9.06%7.09%8.1%6.65%7.47%15.41%12.01%15.88%12.16%8%9.36%15.33%15.84%14.1%12.87%9.86%8.16%4.73%10.44%10.71%8.39%1.23%11.81%10.27%-3.29%3.79%-23.57%
EBITDA Growth %9.94%-6.81%18.19%-21.29%-44.48%62.84%-24.81%48.81%67.19%-11.69%-12.69%6.32%30.17%32.81%66.94%33.4%79.71%-61.6%15.19%75.95%768.34%-89.79%39.51%464.04%-187.49%120.74%-
D&A (Non-Cash Add-back)77.37M78.8M89.75M95.56M99.17M84.93M71.59M64.12M51.35M51.51M58.36M25.64M20.27M18.36M13.32M7.98M8.62M9.43M8.95M4.6M3.72M4.2M4.08M3.5M3.02M3.72M3.65M
EBIT39.45M17.49M337K-15.58M-2.32M89.51M35.53M78.35M44.39M11.14M21.41M45.19M49.58M35.3M27.13M16.15M9.96M1.21M20.74M18.22M9.26M-2.3M10.72M7.94M-3.46M-580K-16.63M
Net Interest Income5.26M-6.17M20.38M14.76M-130K-22.39M-2.1M-5.8M000-2.39M-1.08M-270K-51K204K420K604K3.4M00000000
Interest Income7.3M024.9M14.76M00000000030K77K266K424K619K3.42M00000000
Interest Expense2.14M6.17M4.53M0130K22.39M2.1M5.8M0002.39M1.08M122K29K62K4K15K15K00000000
Other Income/Expense4.13M6.17M25.26M-779K-130K-23.5M-6.18M-4.42M-8.78M-6.63M-8.43M-2.39M-1.08M-270K-51K-133K431K523K3.38M6.05M1.91M651K379K565K875K-577K-1.16M
Pretax Income37.76M11.32M25.59M-20.11M-2.45M66.01M29.35M73.93M35.62M-879K-1.95M46.24M48.5M35.03M27.03M16.09M9.96M1.19M20.72M24.28M11.17M-2.05M10.93M7.55M-5.03M-1.01M-20.69M
Pretax Margin %3.08%0.96%2.3%-1.75%-0.19%5.83%3.29%8.24%4.52%-0.12%-0.28%9.54%11%9.2%8.61%6.55%4.48%0.56%8.23%11.39%7.22%-1.69%8.82%7.39%-5.73%-1.16%-30.71%
Income Tax17.33M9.27M13.06M263K-8.1M-11.84M-2.85M12.6M-2.11M-21.48M-2.55M15.48M17.99M11.05M10.87M5.7M5.07M748K8M-19.02M804K20K324K242K10K160K100K
Effective Tax Rate %45.89%81.88%51.04%-1.31%330.25%-17.94%-9.69%17.04%-5.93%2444.14%130.95%33.48%37.08%31.55%40.22%35.43%50.87%62.75%38.6%-78.34%7.2%-0.97%2.97%3.21%-0.2%-15.89%-0.48%
Net Income20.43M2.05M12.53M-20.37M5.65M77.85M32.19M61.34M37.73M20.61M603K30.76M30.52M23.98M16.16M10.39M4.89M444K12.72M43.3M10.37M-2.07M10.6M7.31M-5.04M-1.17M-20.79M
Net Margin %1.67%0.17%1.13%-1.78%0.44%6.88%3.61%6.84%4.79%2.88%0.09%6.35%6.92%6.3%5.15%4.23%2.2%0.21%5.05%20.32%6.7%-1.71%8.55%7.15%-5.75%-1.34%-30.86%
Net Income Growth %-3.55%-83.62%161.51%-460.68%-92.74%141.81%-47.51%62.58%83.11%3317.08%-98.04%0.79%27.27%48.38%55.56%112.37%1001.8%-96.51%-70.61%317.7%599.76%-119.56%45.09%245.04%-331.71%94.39%-
Net Income (Continuing)20.43M2.05M12.53M-20.37M5.65M77.85M32.19M61.34M37.73M30.52M603K30.76M30.52M23.98M16.18M10.39M4.89M444K12.72M43.3M10.37M-2.07M10.6M7.31M-5.04M-1.17M-20.79M
Discontinued Operations000000000000000000000000000
Minority Interest000000000000000000000000000
EPS (Diluted)0.440.040.27-0.450.121.620.741.430.930.790.260.840.830.670.470.300.150.010.381.280.36-0.080.380.29-0.23-0.11-12.20
EPS Growth %-3.51%-83.59%160%-475%-92.59%118.92%-48.25%53.76%17.72%203.85%-69.05%1.2%23.88%42.55%56.67%100%1400%-97.37%-70.31%255.56%549.44%-121.08%31.03%226.09%-109.09%99.1%-
EPS (Basic)-0.040.27-0.450.131.790.761.480.960.810.270.860.860.690.490.310.150.010.401.350.38-0.080.430.32-0.23-0.11-12.20
Diluted Shares Outstanding45.94M46.36M46.26M45.21M45.89M47.94M43.74M42.94M40.56M38.71M36.86M36.72M36.62M35.78M34.21M34.1M33.51M32.06M33.11M33.82M28.9M25.91M27.72M25.32M21.73M10.31M1.7M
Basic Shares Outstanding45.32M45.97M46.05M45.21M44.4M43.48M42.58M41.46M39.24M37.48M36.16M35.86M35.65M34.74M33.31M33.12M32.65M31.69M32.08M32.08M27.34M25.91M24.85M22.75M21.73M10.31M1.7M
Dividend Payout Ratio---------------------------

Key Metrics

Growth RegimeMixed
ProfitabilityStrained
Balance SheetHealthy
Cash FlowMixed
Top Statement Risk

Hospital CAPEX budget sensitivity

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Growth Exhibits Cyclical Volatility

According to the provided quarterly data, Omnicell's revenue growth has fluctuated significantly, ranging from a 15.3% contraction in 2024Q1 to a 18.6% expansion by 2024Q4, suggesting that the company's top-line performance remains highly sensitive to hospital capital expenditure cycles and the timing of large-scale system installations.

The erratic revenue trajectory appears to reflect the inherent lumpiness of hardware-heavy medical equipment sales, where revenue recognition is tied to project go-live dates. While the recent shift toward subscription-based Advanced Services aims to smooth these cycles, the current data suggests that the business remains vulnerable to the budgetary constraints of its primary hospital customer base.

Structural Margin Pressure Remains Persistent

As reported in financial statements, Omnicell's gross margin has struggled to maintain consistency, oscillating between a low of 38.7% in 2024Q1 and a peak of 46.6% in 2024Q4, indicating that inflationary pressures on manufacturing components and logistics continue to weigh on the company's core profitability.

The inability to sustain gross margins above the 45% threshold suggests that the company lacks the pricing power necessary to fully offset rising input costs. Investors should monitor whether the transition to higher-margin software services can eventually decouple the company's profitability from the volatile costs associated with its hardware-centric manufacturing model.

Operating Leverage Remains Severely Constrained

Based on the income statement data, Omnicell's operating margin reached a razor-thin 0.44% in 2025Q4, demonstrating that the company's high fixed-cost base in R&D and SG&A effectively absorbs nearly all gross profit generated during periods of moderate revenue growth, leaving little room for operational error.

The lack of meaningful operating leverage suggests that the company's current scale is insufficient to support its heavy investment in software development and administrative overhead. Without a significant acceleration in revenue that outpaces these fixed costs, the company may continue to struggle with achieving consistent, meaningful profitability.

Earnings Quality Impacted by SBC

Analysis of the reported figures reveals that stock-based compensation, which reached $11.2M in 2025Q3, frequently exceeds the company's quarterly net income, suggesting that reported EPS figures may significantly overstate the actual economic value generated for shareholders after accounting for equity-based dilution and non-cash expenses.

The reliance on stock-based compensation as a significant component of the cost structure warrants further investigation into the company's true cash-generating capability. Investors should be cautious of the gap between GAAP net income and the underlying cash flow, as the current earnings profile appears heavily influenced by non-operating accounting adjustments.

OMCL — Frequently Asked Questions

Quick answers to the most common questions about buying OMCL stock.

What was Omnicell, Inc.'s (OMCL) revenue in 2025?

For fiscal year 2025, Omnicell, Inc. (OMCL) reported total revenue of $1.18B. This represents a 1658.8% increase compared to $67.4M in 2000.

Is Omnicell, Inc. (OMCL) profitable?

Omnicell, Inc. (OMCL) is profitable, generating $2.1M in net income for the fiscal year ending 2025 with a net profit margin of 0.2%.

What is Omnicell, Inc.'s operating profit margin?

Omnicell, Inc. (OMCL) reported an operating income of $5.2M, resulting in an operating profit margin of 0.4%. This margin reflects the operational efficiency of the business before interest and taxes.

What is Omnicell, Inc.'s gross profit and gross margin?

Omnicell, Inc. (OMCL) generated $503.4M in gross profit for the year, representing a gross profit margin of 42.5%. This demonstrates the company's core pricing power and production efficiency.